Navigation Links
Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease
Date:5/15/2009

Cimzia(R) (certolizumab pegol) now offered in an innovative prefilled syringe designed in partnership with OXO GOOD GRIPS(R)

ATLANTA, May 15 /PRNewswire/ --- UCB today announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S. for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy, is now available for self-administration in a prefilled syringe designed in partnership with OXO GOOD GRIPS(R) a company dedicated to providing innovative consumer products that make everyday life easier.

"We looked at a variety of unmet needs for Crohn's disease patients and found that many prefer a prefilled syringe when taking biologic medications," said David Robinson, vice president and general manager of UCB's Immunology Business Unit. "This newly designed, easy-to-use syringe, developed with a renowned consumer products company like OXO(R), will enable many patients to conveniently self-administer their therapy every four weeks."

The Cimzia(R) prefilled syringe, designed by UCB in partnership with OXO GOOD GRIPS(R) is available exclusively for use with Cimzia(R). The companies recognized the importance of designing a syringe and packaging components with the patient in mind to provide ease of use, comfort, control and confidence.

The new syringe provides a soft, non-slip grip on the flange which allows the patients to hold the syringe steady using various grip positions so it is easy and comfortable to use. The large and soft thumb pad on the plunger makes it easy to push for patients. The rounded finger loop allows for easy removal of the needle cover. The easy-to-read syringe barrel helps to ensure patients receive the entire dose as they can see the medicine ins
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
2. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
3. Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohns Patients
4. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. New Online Project Management Fundamentals for Healthcare Module Available
7. KT Tape: Secret Weapon of Elite Athletes - Now Available to Everyone
8. Fiber Technology Products that Help Combat Spread of Superbugs Now Available to the Consumer Market
9. Providence Service Corporation Makes Its Spring 2009 Presentation Publicly Available
10. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
11. Diatherix Laboratories Releases First Clinically Available Test For Confirmation of The Swine Flu Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... scientists have shown that a new drug could prove useful ... form of lung cancer. , Scientists from the Cancer Research ... part of the Manchester Cancer Research Centre, teamed up with ... 2010, to test a drug known as AZD3965 - ... in the journal Clinical Cancer Research , also helps ...
(Date:7/9/2014)... episodes of low back pain are not linked to ... direction and precipitation. Findings published in Arthritis Care ... of Rheumatology (ACR), indicate that the risk of low ... wind gusts, but was not clinically significant. , ... experiences low back pain at some point in their ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, ... ahead of her. , "I was devastated," said Wakulich, who ... "I knew this was a serious diagnosis. Then I met ... that involved a less invasive procedure. It was something I ... participating in a multi-center U.S. clinical trial to evaluate the ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
Breaking Medicine News(10 mins):Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... be saved every year, thanks to a simple online calculator ... having ovarian cancer at a much earlier stage. Academics ... a new QCancer algorithm using the UK QResearch database. The ... factors to red flag those most likely to have ovarian ...
... (HealthDay News) --Families hoping to improve their fitness and overall ... TV or computer screen and more time being active together, according ... the following tips to help your family get moving and stay ... Stroll together after a family meal or walk around the mall ...
... The current issue of Medical Acupuncture , a ... how the U.S. military is incorporating medical acupuncture to ... in the war zones and the efforts underway to ... online at http://www.liebertpub.com/acu . "The use of ...
... press release is available in French . ... liver during digestion, has been seriously underestimated. A study published ... kill several types of cancer cells, such as those found ... research team, led by Concordia University, included scientists from McGill ...
... bowel disease (IBD) are increasing with time and in ... study in Gastroenterology , the official journal of ... worldwide epidemiology of inflammatory bowel disease is important for ... Gilaad G. Kaplan, MD, MPH, of the University of ...
... substances in licorice used extensively in Chinese traditional medicine ... and gum disease, the leading causes of tooth loss in ... of Natural Products , they say that these substances could ... gum disease. Stefan Gafner and colleagues explain that ...
Cached Medicine News:Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 2Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 3Health News:Cancer-killing compound spares healthy cells 2Health News:IBD emerges as a global disease 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... III Study Results Presented At ASCO -- , ... with,pegylated interferon alfa-2b in stage III melanoma had ... to the results of the largest adjuvant trial ... of the Phase,III study, led by the European ...
... - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmaceutical company ... highlights of data presentations made,during the 2007 ... Dacogen (decitabine) for Injection was the subject ... data in older,patients with acute myelogenous leukemia ...
Cached Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
... the needs of the higher risk ... features the PneumaticWalker for Diabetics. Similar ... Diabetics incorporates an innovative dual density ... insole, when combined with the semi-rigid ...
... Sarmiento style Patella-Tendon-Bearing brace is designed for ... tibia and fibula. The tibial crest provides ... medullary nailing and removal of internal or ... of joints above and below the fracture ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy.,All Cryo/Cuffs can be ordered as ... (including a tube assembly and insulation disk). ...
Medicine Products: